SCHEMBL15437833

SCHEMBL15437833

O=C1C(O)=C(c2ccccc2)C(=O)N1c1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAD51 Q06609 1/20 0.51
▸ MGLL Q99685 2/20 0.47
▸ ALDH1A1 P00352 5/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ MEN1 O00255 7/20 0.43
▸ KMT2A Q03164 7/20 0.43
▸ GAA P10253 5/20 0.43
▸ CASP6 P55212 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ PTGS2 P35354 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MAPT P10636 5/20 0.42
▸ HTT P42858 4/20 0.42
▸ PGR P06401 1/20 0.42
▸ PKM P14618 2/20 0.41
▸ FAAH O00519 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15437791 0.89 RAD51 (0.58) RAD51MGLLALDH1A1KDM4ESMN1; SMN2
SCHEMBL15437877 0.85 ESR1 (0.47) RAD51MGLLALDH1A1KDM4EMEN1
SCHEMBL15437867 0.84 RAD51 (0.70) RAD51MGLLALDH1A1KDM4ESMN1; SMN2
SCHEMBL15438309 0.84 MEN1 (0.54) RAD51MGLLALDH1A1KDM4ESMN1; SMN2
SCHEMBL15757929 0.84 RAD51 (0.74) RAD51ALDH1A1KDM4EMEN1KMT2A
SCHEMBL15437773 0.77 MEN1 (0.53) RAD51MGLLKDM4EMEN1KMT2A
SCHEMBL15437881 0.75 MGLL (0.47) RAD51MGLLALDH1A1SMN1; SMN2MEN1
SCHEMBL2553055 0.73 KDM4E (0.68) MGLLALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL11649332 0.73 MGLL (0.64) MGLLALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL14777408 0.72 NR1H2 (0.53) RAD51MGLLALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9296690-B2 Method for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2016-03-29 — — US disclosed
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof METACINE, INC. (KR) 2014-09-18 — — US disclosed
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof METACINE, INC. (KR) 2014-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031563-A1 New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof SOST, MYD88, MSR1 RAD51 1883/4885MGLL 4191/4885ALDH1A1 3334/4885
US-20140275203-A1 Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof SOST, MYD88, MSR1 RAD51 2803/4885MGLL 4069/4885ALDH1A1 2526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback